Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact. To learn more, visit www.triveni.bio.
Location: United States, Massachusetts, Waltham
Total raised: $207M
Investors 2
| Date | Name | Website |
| 18.11.2023 | OrbiMed | orbimed.co... |
| 26.10.2023 | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.10.2024 | Series B | $115M | - |
| 26.10.2023 | Series A | $92M | - |
Mentions in press and media 8
| Date | Title | Description |
| 19.06.2026 | Triveni Bio Raises $65 Million Series C Financing | WATERTOWN, MA, Triveni Bio, a clinical-stage biotechnology company, announced a $65 million Series C financing round. >> Click here for more funding data on Triveni Bio >> To export Triveni Bio funding data to PDF and Excel, cl... |
| 17.06.2026 | Triveni Bio Raises $65M in Series C Funding | Triveni Bio, a Watertown, MA-based biotech company advancing new antibody treatments for I&I disorders, raised $65M in Series C funding. The round was co-led by new investors Ascenta Capital and Janus Henderson Investors, with participa... |
| 04.10.2024 | Triveni Bio: $115 Million (Series B) Closed To Advance Novel Antibody Treatments For I&I Disorders | Triveni Bio, a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B to support pipeline expansion. The funding round was led by Goldman Sachs Alternatives with significant participatio... |
| 02.10.2024 | Triveni Bio Raises $115M in Series B Financing | Triveni Bio, a Watertown, MA-based biotech company advancing novel antibody treatments for I&I disorders, raised $115M in Series b funding. The round was led by Goldman Sachs Alternatives with participation from additional new investors... |
| 02.10.2024 | Triveni Bio Lands $115M Series B | WATERTOWN, MA, Triveni Bio, a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B. >> Click here for more funding data on Triveni Bio >> To export Triveni Bio funding dat... |
| 26.10.2023 | Triveni Bio Raises $92M in Series A | Triveni Bio, a Waltham, MA-based biotech company providing a genetics-informed precision medicine approach for I&I disorders, raised $92M in Series A funding. The round was led by Atlas Venture and Cormorant Asset Management, with parti... |
| - | Triveni Bio | “Home - Triveni Bio” |
| - | Triveni Bio | “Triveni Bio is pioneering a genetics-informed precision medicine approach to develop functional antibodies to treat immunological and inflammatory disorders.” |